The purpose of the study was to evaluate the immunogenicity and describe the safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed Meningococcal polysaccharide groups A, C, W-135 and Y (Nimenrix®) Conjugate vaccine in toddlers 12 to 23 months of age in the European Union (EU). The toddlers were either meningococcal vaccine naïve or had received monovalent meningococcal C (MenC) vaccination during infancy to evaluate any potential impact of the meningococcal vaccine background on the immunogenicity and safety profile of the investigational product.
Primary Objectives:
To demonstrate the non-inferiority of the antibody response to meningococcal serogroups A, C, Y, and W after a single dose of MenACYW Conjugate vaccine or Nimenrix® in toddlers who either were meningococcal vaccine naïve or had received monovalent MenC vaccination during infancy.
To demonstrate the non-inferiority of the antibody response to meningococcal serogroups A, C, Y, and W after a single dose of MenACYW Conjugate vaccine or Nimenrix® in meningococcal vaccine naïve toddlers.
Secondary Objectives:
To compare the antibody responses (geometric mean titers [GMTs]) to meningococcal serogroups A, C, Y, and W after a dose of MenACYW Conjugate vaccine or Nimenrix® as measured by serum bactericidal assay using human complement (hSBA) in toddlers who either were meningococcal vaccine naïve or had received monovalent MenC vaccination during infancy.
To compare the antibody responses (GMTs) to meningococcal serogroups A, C, Y, and W after a dose of MenACYW Conjugate vaccine or Nimenrix® as measured by hSBA in meningococcal vaccine naïve toddlers.
To compare the antibody responses (GMTs) to meningococcal serogroups A, C, Y, and W after a dose of MenACYW Conjugate vaccine or Nimenrix® as measured by hSBA in toddlers who received monovalent MenC vaccination during infancy.

开始日期2017-02-24

申办/合作机构

Sanofi Pasteur

NCT01239043 / Completed临床2期

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® Vaccine Approximately Three Years Following Initial Vaccination in Adults Who Participated in Trial MTA29

The purpose of this trial is to describe antibody persistence and response to re-vaccination with either Menactra® or Menomune® vaccine approximately three years following initial vaccination in adults who participated in trial MTA29 (NCT00874549).
Objectives:
To describe the rates of immediate reactions, solicited injection-site and systemic reactions, all unsolicited adverse events, and serious adverse events following vaccination.
To evaluate persistence of serum bactericidal antibodies in subjects who received Menactra® or Menomune® vaccine approximately three years ago.
To evaluate the immune response to serogroups A, C, Y, and W-135 in subjects re-vaccinated with either Menactra® or Menomune® vaccine.

开始日期2010-11-01

申办/合作机构

Sanofi

NCT00862277 / CompletedN/A

Evaluation of the Persistence of Bactericidal Antibodies in Adolescents and Adults Who Received a Single Dose of Menactra® Four to Eight Years Earlier

To evaluate the persistence of bactericidal antibodies in adolescents and adults who received one dose of Menactra® vaccine approximately four to eight years earlier

开始日期2008-12-01

申办/合作机构

Sanofi Pasteur

100 项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的临床结果

登录后查看更多信息

100 项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的转化医学

登录后查看更多信息

100 项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的专利（医药）

登录后查看更多信息

项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的文献（医药）

2021-09-30·Infectious diseases and therapy3区 · 医学

A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.

3区 · 医学

ReviewOA

作者: Yara Ruiz Garcia ; Véronique Abitbol ; Michele Pellegrini ; Rafik Bekkat-Berkani ; Lamine Soumahoro

The quadrivalent A, C, W and Y meningococcal vaccine conjugated to nontoxic mutant of diphtheria toxin (MenACWY-CRM) has been licensed since 2010 for the prevention of invasive meningococcal disease (IMD), an uncommon but life-threatening condition. Here, we summarize the experience accrued with MenACWY-CRM during the first decade since its licensure, by providing an overview of clinical trials investigating the safety, immunogenicity and co-administration of MenACWY-CRM with other vaccines as well as presenting real-world evidence regarding the impact of MenACWY-CRM vaccination on carriage and IMD incidence. MenACWY-CRM has demonstrated an acceptable clinical safety profile across a wide range of age groups; no safety concerns have been reported in special populations, such as immunocompromised infants and toddlers, or pregnant women. MenACWY-CRM has also been proven to be immunogenic in various age groups and geographic settings, and a booster dose has been shown to elicit strong anamnestic responses in all studied populations, irrespective of the vaccine used for priming. With no clinically relevant vaccine interactions reported, MenACWY-CRM is being conveniently integrated into existing vaccination programs for various age and risk groups; this possibility of co-administration helps improving vaccine coverage and streamlining the healthcare process of fighting preventable infectious diseases. Vaccination of adolescents and adults has been proven to reduce nasopharyngeal carriage for serogroups C, W and Y, which is an important element in reducing transmission. Real-world evidence indicates that MenACWY-CRM can reduce IMD incidence even in high-exposure groups. When combined with vaccines against serogroup B meningococci, MenACWY-CRM can offer protection against five of the most common serogroups responsible for IMD, which is an important advantage in the continuously evolving landscape of meningococcal serogroup epidemiology.

2021-03-25·Journal of clinical pharmacy and therapeutics4区 · 医学

Improving meningococcal MenACWY and 4CMenB/meningococcal group B vaccine-related health literacy in patients: Importance of readability of pharmaceutical Patient Leaflets.

4区 · 医学

Article

作者: Orlaith C Brennan ; John E Moore ; Thomas W Nutt ; Peter Ja Moore ; Beverley C Millar

WHAT IS KNOWN AND OBJECTIVE:

Patient information leaflets (PILs) or Patient Leaflets (PLs) formally accompany dispensed medicines and are intended to provide the patient with information on how to use the medicine safely. To date, there have been no studies that have examined the readability of meningococcal vaccine patient-facing information, including information contained within the vaccine PIL. Given the role of pharmacists in presenting PILs to patients, it was, therefore, the aim of this study to quantitatively analyse the readability of Patient Leaflets, which accompany licensed meningococcal vaccines in the UK and US and to compare PILs to vaccine pharmaceutical manufacturers' summary of product characteristics (SPC), as well as other patient-facing vaccine-related information.

METHODS:

Five sources of meningococcal vaccine information were examined for the licensed meningococcal vaccines in the UK (Bexsero, Menveo, Menitorix, Trumenba, Nimenrix & NeisVac-C) and in the United States (Bexsero, Menveo, Trumenba, Menactra, Menomune-A/C/Y/W-135, Menquadfi), including as follows: (i) SPC (Electronic Medicines Compendium, UK), (ii) Package Insert (FDA; USA), (iii) Patient Leaflet (Electronic Medicines Compendium, UK), (iv) Vaccine pharmaceutical websites and (v) government web resources. Readability was examined employing 10 readability metrics, including the Flesch Reading Ease and the Flesch-Kincaid Grade level.

RESULTS AND DISCUSSION:

The information source with the greatest readability scores was the UK Patient Leaflet, which had a mean Flesch Reading Ease score of 58.1 and a mean Flesch-Kincaid Grade score of 7.3, followed by the US Department of Health & Human Services patient-facing website for vaccines (55.9 & 8, respectively), followed by the US Centers for Disease Control and Prevention Vaccine Information Statement (47.3 & 9.4, respectively). Pharmaceutical patient-facing websites for meningococcal vaccines had mean scores of 44.6 and 9.9, respectively. When compared with UK Patient Leaflets, pharmaceutical websites were statistically different with poorer readability with both Flesch Reading Ease and Flesch-Kincaid Grade Level indices (p = 0.02 & p = 0.04, respectively).

WHAT IS NEW AND CONCLUSION:

Pharmaceutical meningococcal vaccine PILs were easily read and had statistically significant good readability scores in comparison with vaccine SPCs and US Package Inserts, pharmaceutical product websites and other government patient-facing meningococcal vaccine information. Preparation of patient-facing materials of a complex topic, such as describing meningococcal vaccines, is difficult to accomplish. Although there is a plurality of sources of information through websites and social media, PILs are one of the few sources that are provided directly to patients. This underpins the potential importance of PILs and the importance of their readability. Adoption of readability calculators and scrutiny of materials for their readability will help authors develop materials with improved understanding for vaccine recipients, potentially leading to improved health literacy and vaccine uptake. Renewed efforts should be sought to promote the information within the PIL, thereby maximizing the value of this resource with vaccine recipients, their carers and family.

2015-11-15·Clinical Infectious Diseases1区 · 医学

Neisseria meningitidis group A IgG1 and IgG2 subclass immune response in African children aged 12-23 months following meningococcal vaccination

1区 · 医学

Article

作者: Holme, Daniel ; Findlow, Helen ; Sow, Samba O. ; Idoko, Olubukola T. ; Preziosi, Marie-Pierre ; Carlone, George ; Plikaytis, Brian D. ; Borrow, Ray

BACKGROUND:

A group A meningococcal conjugate vaccine, PsA-TT, was licensed in 2010 and was previously studied in a phase 2 clinical trial to evaluate its safety and immunogenicity in African children 12-23 months of age.

METHODS:

Subjects received either PsA-TT; meningococcal group A, C, W, Y polysaccharide vaccine (PsACWY); or Haemophilus influenzae type b conjugate vaccine (Hib-TT). Forty weeks following primary vaccination, the 3 groups were further randomized to receive either PsA-TT, one-fifth dose of PsACWY, or Hib-TT. Group A-specific immunoglobulin G (IgG) subclass response was characterized using an enzyme-linked immunosorbent assay.

RESULTS:

The predominant IgG subclass response, regardless of vaccine, was IgG1. One month following primary vaccination, the geometric mean concentrations (GMCs) of IgG1 and IgG2 in the PsA-TT group were 21.73 µg/mL and 6.27 µg/mL, whereas in the PsACWY group the mean GMCs were 2.01 µg/mL and 0.97 µg/mL, respectively (P < .0001). Group A-specific IgG1 and IgG2 GMCs remained greater in the PsA-TT group than in the PsACWY group 40 weeks following primary vaccination (P < .0001). One week following revaccination, those given 2 doses of PsA-TT had the greatest IgG1 and IgG2 GMCs of 125.23 µg/mL and 36.12 µg/mL, respectively (P = .0008), and demonstrated a significant increase in IgG1:IgG2 mean ratio, indicative of the T-cell-dependent response associated with conjugate vaccines.

CONCLUSIONS:

Vaccination of African children aged 12-24 months with either PsA-TT or PsACWY elicited a predominantly IgG1 response. The IgG1:IgG2 mean ratio decreased following successive vaccination with PsACWY, indicating a shift toward IgG2, suggestive of the T-cell-independent immune response commonly associated with polysaccharide antigens.

CLINICAL TRIALS REGISTRATION:

SRCTN78147026.

项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的新闻（医药）

2024-03-08

·生物制品圈

盘点2023年疫苗界20大影响力事件

2023 TOP20 VACCINE NEWS按时间顺序👇👇👇 01 十部联发，我国发起消除宫颈癌的冲锋号▼ ▼ ▼1月5日，国家卫健委等10部门发布1号文件《加速消除宫颈癌行动计划（2023-2030年）》，我国正式发起消除宫颈癌的冲锋号。据不完全统计，截至12月我国已有30+省市区县开展HPV疫苗试点接种工作（排名不分先后）。 02 弥补需求，国产带状疱疹减毒活疫苗上市应用▼ ▼ ▼1月31日，国家药品监督管理局官网显示，长春百克研发生产的我国首个带状疱疹疫苗（减毒活疫苗）获批上市，适用于40岁及以上人群，仅需接种1剂次。国产带状疱疹疫苗的上市，不仅弥补了我国40-50岁人群的接种需求，也有助于提升我国带状疱疹疫苗接种率。 03 保护升级，自主研发三价轮状病毒疫苗上市▼ ▼ ▼4月17日，兰州生物制品所自主研发的口服三价重配轮状病毒减毒活疫苗获批上市，12月28日获得首个批签发，疫苗适用于6-32周龄婴幼儿。据临床数据显示，该疫苗交叉保护性好，可有效预防G1、G2、G3、G4和G9型轮状病毒导致的婴幼儿腹泻。 04 国货之光，国产二价HPV疫苗不输进口四价▼ ▼ ▼4月17-21日，第35届国际乳头瘤病毒大会（IPVC）上，PATH专家报告了国产二价HPV疫苗（馨可宁）与4价HPV疫苗（佳达修）的头对头非劣效临床试验的中期结果：国产二价馨可宁关于HPV16/18的免疫原性非劣于佳达修。该结果有望为国产HPV疫苗广泛进入国际市场提供证据支持。联合国儿童基金会采购目录显示，馨可宁采购价格为2.9$，低于佳达修（4.5$）和希瑞适（5.18$)。菲律宾、肯尼亚、莫桑比克、布基纳法索均开展了替代HPV疫苗的效果和成本效益模型研究，证实馨可宁可带来相似健康效益和更低的成本。 05 重磅新品，全球两款创新RSV疫苗相继获批▼ ▼ ▼5月3日，FDA批准全球首个由葛兰素史克公司研发的呼吸道合胞病毒（RSV）疫苗Arexvy上市，辉瑞公司紧随其后宣布FDA在6月1日批准其二价RSV疫苗Abrysvo上市。两款疫苗的目标适用人群都是60岁及以上的群体。此外，辉瑞的疫苗还可以应用于孕晚期女性（32-36周）。据美国CDC官网显示，全美每年由RSV所致住院患儿58000-80000例，住院老人60000-160000例，其中6000-10000例死亡。据2009-2019年我国急性呼吸道感染病例病原检测数据显示，我国RSV的全人群检出率仅次于流感病毒。 06 正式官宣，全球结束新冠疫情紧急状态▼ ▼ ▼5月5日，世界卫生组织正式宣布，新冠疫情不再构成“国际关注的突发公共卫生事件”，国际贸易及旅游将有望逐步恢复到COVID-19大流行前的水平。 07 疾控改制，我国疾控系统行政+业务一肩担▼ ▼ ▼5-6月，全国28个省（含自治区）、4个直辖市相继挂牌成立“省级疾病预防控制局”。12月27日，国务院办公厅发布关于推动疾病预防控制事业高质量发展的指导意见，我国疾控改制进入快车道。疾控系统将不仅仅作为承担科研和疾病防控的业务部门，也将担负其行政职能。 08 再次升级，20价肺炎结合疫苗获FDA上市许可▼ ▼ ▼6月8日，辉瑞研发的全球首款20价肺炎球菌多糖结合疫苗PREVNAR 20®获FDA批准在美上市，该款疫苗可用于儿童和成人接种，将覆盖更多血清型、带来更多获益。 09 填补空白，自研诺如双价疫苗进入III期临床▼ ▼ ▼7月3日，中国生物兰州所研发的重组诺如病毒双价疫苗III期临床试验完成首例入组，系全球首个进入III期临床的重组诺如病毒双价疫苗，预期2025年7月完成临床试验，将弥补没有诺如疫苗的市场空白，进一步保障儿童肠道健康。此外，智飞生物的4价、康华生物的6价重组诺如病毒疫苗均进入临床1期或2期。 10 比肩进口，万泰九价HPV疫苗免疫原性优异▼ ▼ ▼7月初，《柳叶刀·感染病学》发表首个国产HPV九价疫苗（万泰生物）与MSD的九价HPV疫苗在16-26岁性中的头对头免疫原性比较研究：9个型别抗体浓度中，其中5个略高、4个略低、总体非劣效于现役唯一一款9价HPV疫苗佳达修9。这将为国产九价HPV疫苗的提前获批上市进一步提供证据，未来有望以更低的价格和相似的效果覆盖更多女性。 11 药监发文，国产九价有望提前获批上市▼ ▼ ▼7月10日，国家药监局药品审评中心发布《人乳头瘤病毒疫苗临床试验指导原则（试行）》，指出迭代疫苗可以预防12个月持续感染作为申报条件，申请提前上市。目前符合该条件的HPV疫苗有万泰生物、沃森生物生产的研发的九价HPV疫苗，两款九价HPV疫苗均已进入III期临床访视阶段。根据股市动态，万泰生物恐先触线突围。 12 100%效力，重组带疱疫苗披露III期数据▼ ▼ ▼8月24日，GSK披露其重组带状疱疹疫苗在中国的III期保护效力试验数据：安慰剂组31例、疫苗组0例，保护效力100%，该数据可被视为对国产减毒带状疱疹疫苗上市动作的有力反击。 13 指南更新，倡议公众广泛接种流感疫苗▼ ▼ ▼9月5日，中国疾控中心发布《流感疫苗预防接种技术指南（2023-2024年）》，建议≥6月龄且无接种禁忌的所有人群接种流感疫苗，以面对今秋冬可能的流感流行。 14 两部发文，狂犬病暴露处置新规范发布▼ ▼ ▼9月16日，国家卫生健康委、国家疾控局发布《狂犬病暴露预防处置工作规范（2023年版）》，将狂犬病暴露分为三级、增加消毒剂使用种类、优化疫苗接种程序和被动免疫制剂使用、扩充高暴露风险者范围。 15 诺奖揭晓，mRNA技术触发疫苗新革命▼ ▼ ▼10月2日，诺贝尔生理学或医学奖揭晓，Katalin Karikó 和 Drew Weissman 因核苷碱基修饰方面的发现而获奖，这些发现使得开发针对COVID-19 的有效 mRNA 疫苗成为可能。目前mRNA技术启发了多个医疗领域的产品研发，研发管线数量仅次于重组蛋白技术，包括但不限于用于改良传统保护效果一般的疫苗、传统工艺无法实现的新疫苗、肿瘤治疗领域新疫苗等。 16 深化代理，智飞再签重磅进口疫苗产品▼ ▼ ▼10月8日，智飞生物与葛兰素史克（GSK）达成合作协议，智飞生物将代理GSK研发生产的重组带状疱疹疫苗和呼吸道合胞病毒RSV疫苗（未来），协议初始期三年。这是继代理默沙东HPV疫苗之后，智飞生物二度与国际疫苗巨头牵手。据估计，重组带状疱疹疫苗自引进国内后，批签发合计不超过300支（截止2023年10月31日）。代理销售仿若智飞生物的财富增长密码据，财报显示，2022年智飞生物91.4%的营收来自于代理产品，2023年上半年这一比例超95%。双方合作能否带来带状疱疹疫苗业务的快速增长，拭目以待。 17 全球首发，五价脑膜炎疫苗获批在美上市▼ ▼ ▼10月20日，辉瑞研发的全球首款五价脑膜炎球菌疫苗Penbraya获FDA批准在美上市。疫苗获批应用于10-25岁青少年群体，覆盖全球最常见的A/B/C/W-135/Y组5个脑膜炎球菌血清型。我国当前主要以脑膜炎A群、C群的控制为主，疫苗应用以多糖疫苗为主，AC群多糖结合疫苗、ACYW135多糖结合疫苗以非免疫规划疫苗应用为主，覆盖率不高。随着我国免疫规划工作的开展，我国脑膜炎奈瑟菌A群、C群得到有效控制。然而2015—2019年我国的流脑病例血清群分布则以B群病例为主，其他依次为C、A、W、Y群及未分群病例。未来该五价脑膜炎疫苗有望在国内上市，弥补空白。 18 4连发，XBB抗原成分疫苗国内相继开打▼ ▼ ▼11-12月，含XBB抗原成分的重组3价（威斯克，XBB.1.5、BA.5、Delta）、重组4价（神州细胞，Beta/BA.1/BQ.1.1/XBB.1）、mRNA二价（石药，XBB.1.5+BQ.1）、mRNA疫苗（沃森&蓝鹊，XBB.1.5）均相继投入市场使用，为我国重点人群预防新冠病毒筑牢屏障。 19 姗姗来迟，新版接种工作规范强化管理▼ ▼ ▼11月30日，国家卫健委疾控局发布《预防接种工作规范（2023年）》，进一步强化预防接种规范化管理。据悉，该规范自《疫苗管理法》发布伊始即在筹备更新，后因疫情搁置。新规范优化和清晰目录设置，增加电子追溯、更新相关定义标准和参考报表，工作要求更科学、适用性更强，为规范和优化预防接种工作提供新标准。 20 业务撤退，辉瑞热门单品交由科园代理▼ ▼ ▼12月1日起，辉瑞解散中国区疫苗销售团队，旗下唯一在境内销售的全球TOP1疫苗产品13价肺炎结合球菌疫苗（沛儿13）将由科园信海代理销售。科园信海将负责该产品在中国大陆地区的独家进口、分销和推广该产品，辉瑞将继续负责产品的开发和生产，并提供必要的专业知识。目前4大跨国疫苗巨头，3家将核心疫苗产品在中国市场的销售交给了本土合作伙伴，唯留一个赛诺菲。目前国内共有3款13价肺炎球菌多糖结合疫苗（其中2款国产），面对竞争压力，交由本土代理销售能否扭转局面尚未可知。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

疫苗上市批准

100 项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07AH04	-

研发状态

适应症	最高研发状态	国家/地区	公司
脑膜炎球菌感染	批准上市	美国更多	Sanofi 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00850603 (CTgov)	临床4期	脑膜炎 \| 脑膜炎球菌感染	170	Menomune (0.5 mL Subcutaneous Menomune®)	鹹膚艱簾窪製衊廠糧範(壓憲襯膚糧獵膚糧構網) = 製夢衊憲築膚齋憲觸醖簾鹹獵糧夢積遞醖鹽憲 (網簾鑰簾顧選艱積鹹糧, 繭衊淵糧範願簾壓獵鏇 ~ 糧憲衊顧選膚顧壓艱醖) 更多	-	2009-04-30
				Menomune (0.1 mL Subcutaneous Menomune®)	鹹膚艱簾窪製衊廠糧範(壓憲襯膚糧獵膚糧構網) = 淵淵簾膚製鏇網鬱遞窪簾鹹獵糧夢積遞醖鹽憲 (網簾鑰簾顧選艱積鹹糧, 廠憲積艱蓋範觸簾壓糧 ~ 壓鑰選構構鏇製衊觸艱) 更多
NCT01239043 (CTgov)	临床2期	流行性脑脊髓膜炎	139	Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide (Menomune® Vaccine Group)	(簾繭遞夢窪鹹鹹製壓鹽) = 襯蓋壓鬱築齋淵膚鏇網廠顧膚獵襯憲構獵選鏇 (窪膚襯襯憲糧願衊願廠, 積構積憲築繭鏇鏇膚範 ~ 鏇齋夢廠襯蓋夢淵遞憲) 更多	-	2012-06-19
				Menactra®: Meningococcal (A, C, Y (Menactra® Vaccine Group)	(簾繭遞夢窪鹹鹹製壓鹽) = 夢鹽壓鬱窪獵齋齋構繭廠顧膚獵襯憲構獵選鏇 (窪膚襯襯憲糧願衊願廠, 製獵獵獵糧簾簾餘製衊 ~ 積餘艱鑰遞鹽鬱襯鹹淵) 更多
Pubmed \| Drugs Aging	N/A	-	400	Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) (MenACWY-TT)	鏇鑰襯鹽餘築壓繭構膚(遞齋範窪鑰築糧鹹鬱鹹) = 選憲願壓選築製廠醖糧醖觸獵淵糧醖餘襯壓鹹 (淵選鹹願獵壓鑰膚鏇膚 ) 更多	-	2013-05-01
				Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) (MenPS)	齋積壓獵顧鑰獵壓廠範(鑰壓範繭鹽鹹繭艱壓壓) = 願醖淵遞夢鏇積憲餘壓顧蓋鹹範蓋遞壓網積範 (鹽鬱觸鹽鏇窪鏇糧積齋 ) 更多
NCT02955797 (CTgov)	临床3期	流行性脑脊髓膜炎	918	W) Tetanus Toxoid Conjugate Vaccine (Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine)	繭襯蓋積鏇糧壓衊範鹽(餘獵壓鏇淵醖選襯顧選): Percentage difference = 1.3 (95% CI, -3.6 ~ 6.2); Percentage difference = 18 (95% CI, 13.6 ~ 22.8); Percentage difference = 1.6 (95% CI, -2.76 ~ 6.03); Percentage difference = 0.2 (95% CI, -5.85 ~ 6.18) 更多	-	2020-06-09
				Y Conjugate vaccine+Meningococcal polysaccharide groups A, C, W-135 (Group 2 (Meningococcal Vaccine-Naive): Nimenrix®)